IGF-1 LR3 is a modified growth signal claimed to increase muscle growth, strength and recovery.
What IGF-1 LR3 does and why that matters
IGF-1 LR3 is a modified form of IGF-1 designed to interact differently with the proteins that normally carry and control IGF-1. It activates growth signals that can increase tissue building in animal experiments. It is claimed to increase muscle and recovery, but those outcomes have not been established in people. The approved IGF-1 medicine mecasermin is a different molecule with a narrow pediatric indication. [1,2,3]
Function evidence: Laboratory and animal growth signaling; no established human LR3 benefit
What people hope to notice
The usual promise is more muscle, greater strength or faster recovery between training sessions. The studies cited for IGF-1 LR3 do not show those outcomes in people. They examined cell behavior and anabolic effects in rats treated with dexamethasone, not healthy adults following a training program. Mecasermin cannot be used as a substitute for that missing evidence because it is a different molecule approved for a narrow pediatric condition. There is no established human bodybuilding dose or predictable benefit for IGF-1 LR3. [1,2,3]
What supports this description: Preclinical growth research; human strength and muscle outcomes not established
IGF-1 LR3 Dosing status
Dose: No established human therapeutic dose | Frequency: No validated bodybuilding schedule | Cycle: No established cycling schedule | Route: No approved human route for LR3
Preparation: No FDA-approved preparation instructions for LR3.
Human pharmacokinetics, dose selection and safety cannot be inferred from these preclinical studies or from mecasermin's label. [1,2,3]
IGF-1 LR3 Effects
Cell experiments. Changes in IGF-binding-protein interactions affected biological activity in cultured cells. The findings do not establish increased muscle growth in people. [1]
Animal experiments. LR3 was studied in dexamethasone-treated rats, an experimental model of a catabolic state. Results cannot be converted into a validated bodybuilding regimen. [2]
IGF-1 LR3 Side Effects
Uncharacterized human risks. Human LR3 risk frequencies are not established by these studies. Mecasermin's label documents serious hypoglycemia and other risks, but its event rates and management instructions cannot be transferred to LR3. Eating around an injection does not establish that experimental LR3 use is safe. [1,2,3]
Frequently Asked Questions About IGF-1 LR3
Is IGF-1 LR3 the same product as Increlex?
Increlex contains mecasermin, recombinant human IGF-1 with the native sequence. LR3 is a modified research analogue. They have different identities and evidence. [1,3]
Is a 20–30-hour human half-life established?
The cited LR3 cell and rat studies do not establish that human estimate. A validated human pharmacokinetic study would be needed. [1,2]
Evidence
Preclinical evidence. The cited LR3 work concerns cell experiments and rats. It does not establish human muscle-building benefits, a human half-life or safe bodybuilding protocols. [1,2]
Approval status: No FDA-approved IGF-1 LR3 product
References
Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol, 1992. PMID 1378742
Tomas FM, Knowles SE, Owens PC, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J, 1992. PMID 1371669
Eton Pharmaceuticals Increlex (mecasermin) prescribing information DailyMed, 2025. Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
